Wire · opportunities
Why oral GLP-1s could create new manufacturing bottlenecks
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 September 2026 · Fusion42 review
Oral GLP-1 therapies, such as Novo Nordisk’s semaglutide and Eli Lilly’s orforglipron, are increasing demand for active pharmaceutical ingredients and specialist excipients, creating new production bottlenecks upstream in the manufacturing supply chain. Manufacturers need enhanced visibility and scenario planning tools to anticipate material shortages and supply disruptions to meet growing market demand.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face new supply bottlenecks from the rising need for specialist inputs in oral GLP-1 drugs. Strengthen your supply chain by gaining early visibility on material availability and run production scenarios this week to avoid costly shortages.
◆ Coverage
1 source · 9 Sep 2026
◆ Related on Wire
◆ Topics